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Despite a slight improvement on statistical data, cardiovascular diseases are still 
among the highest risk factors of mortality rates all over the world. The number of patients die 
due to cardiovascular (CV) diseases is doubled than due to cancer. Since the treatment of CV 
patients an increasing burden on the national economy, it is clear that better (cost-effective) 
treatment options and new prevention strategies are becoming increasingly important, which 
are less expensive than treatment of the disease. Nowadays, the secondary prevention 
strategies, e.g. slowing or stopping the progression of the disease, and identification of the 
„high risk” populations to reduce their risk factors, are becoming more relevant than the 
primer prevention strategy itself. Recently, an emerging trend shows that beside the synthetic 
drugs the use of bioactive compounds as preventing purposes or as pharmaceutical agent 
become more important. A cheaper production process of plant derivatives or more favorable 
side effects could be in the background. An increasing number of studies on animal models 
report that prophylactic administration of certain plant extracts or natural substances 
significantly reduce ischemia / reperfusion (I / R) injuries. Sour cherry seed is a possibly 
active natural material and it is available in large quantities as an industrial byproduct in 
Hungary. 
 Oxidative stress, which biochemical process could be characterized by a great amount 
of oxygen and nitrogen species, and it is one of the most cardinal cellular damaging factors. 
Materials generated by partial reduction of oxygen are extremely instable and reactive agents. 
At normal conditions in eukaryotes they are generated by different metabolic processes, 
respiration, and phagocytosis and through the effect of gowth factors and cytokines. In order 
to balance the toxic effects of reactive oxygen species (ROS) cells utilize both enzymatic and 
non-enzymatic processes. The latter applies e.g. glutation, ascorbic acid, α-tokoferol, while 
superoxide dismutase, catalase, glutathion and heme oxygenase are among the applied 
enzymatic conditions. 
 Heme oxygenases are evolutionarily conservated enymes which catalyse the first step 
of degradation of heme. Certain endproducts of the catabolism play a crucial role of several 
important physiological processes of the organisms as an antioxidant, antiapoptotic-, anti 
inflammatory-, anti proliferatory-, vasoactive, antithrombotic and angiogenesis supporting 
agent. These processes assist the cell survival after different injuries. 
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 Previously we have investigated the effect of the sour cherry seed extract (SCSE) 
against injury caused by I/R. Based on our findings, SCSE decreases infarct size and the 
incidence of ventricular fibrillations (VF) as a dose dependent manner and it improves 
postischaemic heart functions and decreases caspase-3 expression. 
Nevertheless, more exact underlying mechanisms were still unclear. Furthermore, 
another investigation of our team showed that SCSE was capable to reduce the I/R injury of 
rat retina at least by part of inducing heme oxygenase-1 (HO-1) expression. Therefore we 
hypothesized wether SCSE is susceptible to induce HO-1 expression in the heart tissue as 
well. Additionally, we aimed to research the exact role of HO-1 preventing myocardial injury 
caused by I/R and to examine the responsibility of the possible HO-1 overexpression to the 




Materials and methods 
 
Animals  
Male Sprague Dawley rats (220-300 g) and wild-type non-transgenic (NTg), HO-1 Tg 
and HO-1 knock out (KO
-/-
) mice (25–35 g) (Charles Rivers Laboratories, Sulzfeld, 
Germany), were used for the studies. All animals were housed and treated according to the 
“Principles of Laboratory Animal Care” formulated by the National Society for Medical 
Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the 
National Academy of Sciences and published by the National Institutes of Health (NIH 
Publication no. 86-23, revised in 1996). Maintenance and treatment of animals used in this 
study was additionally approved by the Institutional Animal Care and Use Committee of the 
University of Debrecen, Debrecen, Hungary. Rats and mice were fed with commercial food 
pellets and water ad libitum. 
 
Transgenic mice 
Tg were generated as described by Araujo et al.. In brief, CFY mouse eggs were 
injected with 52 kb rat HO-1 construct containing 27.7 kb of the 5’ upstream region, 8.3 kb of 
HO-1 gene and 16 kb of the 3’ downstream region. Cloning was carried out by PCR of rat 
genomic P1 library with two sets of PCR primers corresponding to the first exon (5’-GCT-
TCG-GGGT-TAT-CTG-CCG-TTA-T-3’ and 5’-CAG-TCT-TAC-AGG-CGG-GGA-
ATGTGA-G-3’), and the fifth exon of rat HO-1 gene (5’-GAG-ACG-CCC-CGAGGA-AAA-
TCC-CAG-AT-3’ and 5’-CCC-AAG-AAA-AGA-GAG-CCA-GGCAAG-AT-3’). Two clones 
were identified as positives, and restriction mapping showed that both of them included the 
same insert. The 52 kb band was equivalent to the HO-1 gene and flanking regions. This 52 
kb fragment, including the native HO-1 gene and its promoter, was excised and digested with 
β-agarase, and then microinjected. Mice were genotyped by PCR using the set of primers 
specific for rat HO-1 exon 5. 
HO-1 knock out (KO) mice were also used during these experiments. This model were 
created by targeted mutation of HMOX1 gene. Homozygotes (-/-) for this mutation were 




Treatment of rats with sour cherry seed extract 
Animals were segregated into 2 test groups as described: Group 1—Animals were 
treated orally with 30 mg/kg SCSE (suspended in 2% hydroxyethylcellulose solution) daily 
for a time period of 8 weeks; Group 2—Animals in this group received vehicle solution (2% 
hydroxyethylcellulose solution) for the same time period.  
 
Treatment of mice 
 Transgenic mice were segregated into 2 groups. A group recieved 50 µmol/kg tin-
protoporphyrin-IX (SnPPIX) intraperitoneally 24 hours before performing isolated working 
heart experiments. The SnPPIX was used as a specific inhibitor of HO-1. 
 
Isolated working heart experiments 
Rats were anesthetized by ketamine–xylazine (50/10 mg/kg, intraperitoneally), while 
mice recieved sodium pentobarbital (60 mg/kg, intraperitoneally) and all animals were 
heparinized (1000 IU/kg). Thoracotomy was subsequently performed under terminal 
anesthesia, followed by excision of hearts and placement of the organs in ice-cold modified 
Krebs–Henseleit buffer containing 118 mM NaCl, 5.8 mM KCl, 1.8 mM CaCl2, 25 mM 
NaHCO3, 0.36 mM KH2PO4, 1.2 mM MgSO4 and 5 mM glucose. After the thoracotomy, the 
hearts were cannulated through the aorta and perfused in a Langendorff apparatus in 
“nonworking” mode (100 cm H2O) for 5 minutes to cleanly flush blood from vessels of the 
organ. During the Langendorff perfusion, the pulmonary vein was cannulated, and the 
preparatum was switched to working mode by closing aortic inflow then opening the 
pulmonary flow into the heart with a standard pressure (17 cm H2O). The perfusion buffer 
was previously saturated with a mixture of 95% O2 and 5% CO2, pH 7.4 at 37 °C.  
 
Induction of ischaemia 
After aerob perfusion in experiments with rat hearts global ischemia was induced for 
30 min. while the experiments with mice hearts ischaemia induced for 20 min. followed by  
2 hrs of reperfusion. To prevent the myocardium from drying out, the heart chamber, in which 
hearts were suspended, was covered and the humidity was kept at a constant level (90–95%). 
The first 10 minutes of reperfusion was conducted in Langendorff mode to avoid the fatal 
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ventricular arrhythmias. If VF developed and the sinus rhythm did not spontaneously return 
within the first 2 min. of reperfusion, hearts were electrically defibrillated by a defibrillator 
using two silver electrodes and 15 V square-wave pulse of 1 msec. duration and reperfused. 
Cardiac function assessment on rat hearts 
To examine the recovery of the left ventricle, cardiac function was assessed after 30-, 
60-, and 120-minutes reperfusion. During the entire experimental procedure, aortic pressure 
(AOP) was measured by computer acquisition system (ADInstruments, PowerLab, Castle 
Hill, Australia). Heart rate (HR) and the first derivative of the aortic pressure (AOdP/dt) were 
calculated from the continuously registered AOP. Coronary flow (CF) was measured by the 
timed collection of the effluent dripping from the heart. Aortic flow (AF) was measured using 
a calibrated flow meter. Cardiac output (CO) was generated as a sum of AF and CF. Stroke 
volume (SV) was calculated as the quotient of CO/ HR. Decrement of SV was calculated as a 
ratio of SV at reperfusion divided by baseline SV and multiplied by 100. 
 
Registration of VF and measurement of cardiac function on mouse hearts 
Epicardial electrocardiograms (ECGs) were recorded throughout the experimental 
period by two silver electrodes attached directly to the heart and connected to a data 
acquisition system (ADInstruments, Powerlab, Castle Hill, Australia). ECGs were analysed to 
determine the presence or absence of VF. Hearts were considered to be in VF if an irregular 
undulating baseline was apparent on ECGs. If the duration of VF was longer than 2 min. the 
VF was defined as sustained VF, otherwise, the VF was non-sustained. If VF developed and 
the sinus rhythm did not spontaneously return within the first 2 min. of reperfusion, hearts 
were electrically defibrillated by a defibrillator using two silver electrodes and 15 V square-
wave pulse of 1 msec. duration and reperfused. AF and CF rates were measured by a timed 
collection of the aortic and coronary effluents that dripped from the heart. Before ischemia 
and during reperfusion, heart rate (HR), CF and AF were registered. AOP and AOPdp/dt were 
measured by a computer acquisition system (ADInstruments). 
 
Protein isolation and Western blot analysis 
Approximately 300 mg of the previously freezed and kept at -70 °C heart tissue were 
homogenized using a polytron homogenizer in isolating buffer (25 mM Tris-HCl, 25 mM 
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NaCl, 1 mM orthovanadate, 10 mM NaF, 10 mM pyrophosphate, 10 mM okadaic acid, 0.5 
mM EDTA, 1 mM PMSF, and 1· protease inhibitor cocktail) and centrifuged at 2000 rpm at  
4 °C for 10 minutes. The supernatants were transferred to a new tube and centrifuged at 
10,000 rpm at 4 °C for 20 minutes, after which the resulting supernatant was used as cytosolic 
fraction. The protein concentration was measured by a BCA Protein Assay Kit (Thermo 
Scientific, Rockford, IL). A total of 50–100 mg of protein in each sample were loaded and 
resolved using SDS-PAGE electrophoresis and then transferred to a nitrocellulose membrane. 
After blocking the membranes with 5% of nonfat dry milk in TBST for 1.5 hours, membranes 
were incubated overnight with primary antibody solution at 4 °C (Bcl-2 1/1000, Akt 1/1000, 
p-Akt 1/1000, HO-1 1/1000, and GAPDH 1/20,000; all antibodies were obtained from Cell 
Signaling Technology, Boston, MA). Subsequently, the membranes were washed in TBST 3 
times and incubated with the horseradish peroxidase-conjugated secondary (Cell Signaling 
Technology) antibody solution containing 1% of nonfat dry milk in TBST for an hour at room 
temperature. After washing, the membranes were treated with Western blot Enhanced 
Chemiluminescent HRP substrate (Millipore, Billerica, MA) to visualize the bands. After the 
Enhanced Chemiluminescent treatment, the membranes were exposed on x-ray films (Agfa-
Gevaert N. V., Belgium). The films were then digitalized and analyzed using ImageJ 
program. 
Mouse myocardial samples from LV, RV and S were homogenized in Tris-HCl (13.2 
mM/l), glycerol (5.5%), SDS (0.44%) and β-mercaptoethanol. The same amount of soluble 
protein (50 µg) was fractionated by Tris-glycine- SDS-PAGE (12%) electrophoresis, and 
Western blot was carried out as described by Pellacani et al. by using an antibody for 
recombinant rat HO-1 protein. 
 
Infarct size assessment 
The estimations of infarct size were carried out using the triphenyl tetrazolium 
chloride (TTC) method. Briefly, after 30 minutes of ischemia and 120 minutes of reperfusion, 
rat hearts were perfused with 40 ml 1% (wt/vol) solution of TTC in phosphate buffer, and the 
samples were stored at -70 °C for subsequent analysis. The frozen samples were sectioned, 
weighted, and blotted dry. The dried sections were scanned on an Epson J232D flat-bed 
scanner. The infarcted area (identificable by white coloration) and the risk area (entire 
scanned section) were measured using planimetry software (ImageJ). Estimates of infarcted 
zone magnitude were subsequently obtained by multiplying infarcted areas by weight of each 
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slice. The resulting numbers represent weight of the risk zone and the infarcted zone. Infarct 
size was expressed as a ratio of the weight of infarcted tissue and the weight of risk zone 
(whole heart). We carried out the same protocol at mice hearts, but 10 ml of TTC solution was 
enough to stain the hearts. 
 
Immunohistochemistry 
After reperfusion, the hearts were fixed in 4% of buffered paraformaldehyde solution 
(pH 7.4), embedded in paraffin, and sectioned into 5 µm slices. After deparaffinising the 
sections in xylene, a graded series of alcohol rinses were used to rehydrate the samples. 
Antigen retrieval was accomplished by boiling the slides in 10 mM sodium citrate (pH 6.0) 
containing 0.05% of Tween 20 for 25 minutes in a pressure cooker. H2O2 containing methanol 
was used for 30 minutes at room temperature to block endogen peroxidases. Slides were then 
blocked with 5 % FBS in TBST for 1 hour at room temperature. After blocking, the slides 
were washed with TBST and incubated overnight with a primary antibody (Covalab, France) 
diluted in PBST (1/100) at 4 °C. After washing, the slides were incubated with HRP-
conjugated secondary antibody for 1 hour at room temperature (1/300 dilutions). To visualize, 
DAB solution (Novolink Polymer Detection System; Leica Biosystems, Newcastle, United 
Kingdom) was used. The slides were then washed and covered with mounting medium. Light 
microscopic images were obtained by a Zeiss Axioscope microscope. 
 
RT-PCR 
RNA was prepared from the left ventricles (LVs), right ventricles (RVs), and septum 
(S; about 50 mg) by guanidine isothiocyanate acid/phenol method, and 5 µg total RNA was 
used to synthesize first strand cDNA by the SuperScript First-Strand Synthesis System for 
RT-PCR (Invitrogen, San Diego, CA, USA). The product of cDNA was amplified by PCR 
with specific primers for rat HO-1 exon 5 (CCC-TTC-CTG-TGT-CTT-CCT-TTG and 
ACAGCC-GCC-TCT-ACC-GAC-CAC-A). The product of RT-PCR was separated using 




Measurement of HO activity 
Fifty milligrams of tissue were homogenized in 10 ml of 200 mM phosphate buffer, 
and then centrifuged at 19000 g 4 °C for 10 min. The supernatant was removed and 
recentrifuged at 100000 g 4 °C for 60 min., and precipitated fractions were suspended in 2 ml 
of 100 mM K-phosphate buffer. Biliverdin reductase was crudely purified and HO activity 
was then assayed. Reaction mixtures consisted of (final volume 2 ml) 100 µM K-phosphate 
(pH 7.4), 15 nM hemin, 300 µM bovine serum albumin, 1 mg biliverdin reductase and 1 mg 
microsomal fraction of cardiac tissue. The reaction was allowed to proceed for 1 hr at 37 °C 
in dark in a shaking water bath and was stopped by placing the test on ice. Incubation 
mixtures were then scanned using a scanning spectrophotometer, and the amount of bilirubin 
was calculated as the difference between absorbance at 464 and 530 nm. Proteins were 
determined by the method of Lowry et al., in microsomal fractions. 
 
Measurement of CO 
Tissue CO content was detected using gas chromatography. Hearts were homogenized 
in 4 volumes of 0.1 M phosphate-buffer (pH 7.4) using an 520 homogenizer (Ingenieurburo 
CAT, M. Zipperer GmbH, Staufen, Germany). The homogenates were centrifuged at 4 °C 
for 15 min. at 12,800 g and the supernatant fractions were used for the determination of tissue 
CO content. The reaction mixtures contain: 150 µl of supernatant, 60 µl of NADPH (4.5 mM) 
and 50 µl of 3.5/0.35 mM methemalbumin, and for blank samples 60 µl phosphate buffer was 
used instead of NADPH. Samples were pre-incubated at 37 °C for 5 min., then the headspace 
was purged and the incubation was continued for 1 hr in dark at 37 °C. The reaction stopped 
by placing the samples on ice and the headspace gas was analysed. One thousand microlitres 
of the headspace gas from each vial was injected into the gas chromatograph using a gastight 
syringe (Hamilton Co., Reno, NV, USA) in hydrogen gas flow with a speed of 30 ml/min.. 
Analysis took place during the next 150 sec. on a 200 cm stainless-steel column with a 0.3 cm 
inner diameter. The detector was a thermal conductivity detector with an AC current of 80 
mA. The individual value was expressed in millivolts. The column was packed with Molselect 
5 Å and maintained at 30 °C. The temperature of the injector and detector was controlled and 




Measurement of intracellular Na+, K+ and Ca2+ 
Cellular cations were measured as previously described. In brief, hearts were rapidly 
cooled to 0–5 °C by submersion in, and then perfused for 5 min. with an ice-cold ion-free 
buffer solution containing 100 mmol/l of trishydroxy-methyl-amino-methane and 220 mmol/l 
of sucrose to wash out ions from the extracellular space and to stop enzyme activities 
responsible for membrane ion transport processes. Five minutes of cold washing of the heart 
washed out > 90% of the ions from the extracellular space. Following the wash out period, 
left ventricular tissues were dried for 48 hrs at 100 °C, and made ash at 550 °C for 20 hrs. 
The ash was dissolved in 5 ml of 3 M nitric acid and diluted 10-fold with ion-free deionized 
water. Cellular Na
+
 was measured at a wavelength of 330.3 nm, K
+
 was measured at 404.4 
nm, and Ca
2+
 at 422.7 nm in air-acetylene flame using an atomic absorption 
spectrophotometer (Perkin-Elmer 1100-B, Perkin-Elmer, Waltham, MA, USA). This method 
for the measurement of cellular ion contents has been previously described in the myocardium 
and central nervous system. 
 
Statistical analyses 







infarct size were expressed as mean ± standard error of mean (S. E. M.). The student’s t-test 
was performed, and a level of p <0.05 was considered to be statistically significant. For 
Western blot analysis, repeated measures of ANOVA followed by Tukey’s post-hoc test were 
accomplished. If differences were established the values of NTg group were compared to 
those of HO-1 Tg, and HO-1 KO
-/-
 groups by multiple t-test followed by Bonferroni test. 
Because of the non-parametric distribution of the incidence of VF (sustained and non-
sustained), the χ2 test was used to compare individual groups. A change of P <0.05 was 
considered to be statistically significant. For statistical analysis, we have used the Graphpad 






Augmentation of postischemic left ventricular function by SCSE treatment 
The cardioprotective effect of SCSE treatment was assessed in hearts from rats 
pretreated with the extract for a period of 8 weeks. Each heart was subjected to 30 min of 
global ischemia and 120 min of reperfusion as described above. Enhanced postischemic 
ventricular function was observed in the SCSE- treated group. For example, after 30 minutes 
of ischemia and 120 minutes of reperfusion, COUT was significantly greater in SCSE-treated 
hearts with a value of 59.9 ± 3.4 mL/min than in hearts from vehicle-treated control animals, 
which exhibited COUT values of 44.2 ± 6.0 mL/min. Similar improvements were noted in 
measurements of AF, AOP, and AOdP/dt and decrement in SV in hearts from SCSE-treated 
animals. Moreover, SV showed a trend, albeit nonsignificant, towards enhancement in the 
SCSE-treated hearts. However, no significant difference was observed in HR and CF between 
groups. 
 
SCSE-mediated effects on infarct size 
To further confirm the cardioprotective effect of SCSE, infarct size was measured 
using the TTC method. The extent of infarction zones in hearts from SCSE-treated animals 
were 11.8% ± 3.6%, which was significantly lower in comparison with the vehicle-treated 
control value of 27.7% ± 4.1%, further supporting the cardioprotective properties of SCSE. 
 
SCSE-mediated effects on survival signaling 
Assessment of cell survival signaling in this study was made through measurements of 
the level of antiapoptotic protein Bcl-2 and the ratio of phosphorylated to nonphosphorylated 
Akt (p-Akt/Akt) in cardiac tissue. These experiments were conducted based on outcomes of a 
previous study suggesting that SCSE might modulate these and related homeostatic signaling 
processes. This investigation shows that SCSE treatment upregulates Bcl-2 expression in the 
heart, thereby suppressing apoptosis and inducing the survival of the cardiac tissue after I/R 
challenge. Moreover, a nonsignificant trend toward enhancement of p-(473)Akt/Akt ratio in 
SCSE-treated hearts was noted, but it did not reach the significant level. Cell death as a result 
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of I/R injury may occur as a result of both necrotic and apoptotic processes. Previous studies 
demonstrate the ability of plant polyphenols to suppress apoptosis and infarct size. Results of 
this study further validate these outcomes and lend additional support for the possibility 
for use of SCSE in cardioprotection.  
 
SCSE-mediated effects on HO-1 expression 
Our team previously demonstrated that SCSE-mediated induction of HO-1 in the 
retina strongly protects against ischemia/reperfusion injury. This study measured SCSE 
dosage effect on HO-1 expression in I/R-injured rat myocardium. The results of Western blot 
analyses reveal elevated HO-1 protein expression in the myocardium of SCSE-treated rats 
before and after I/R injury in comparison with the vehicle-treated control hearts. Consistent 
with these outcomes, immunohistochemical analysis of heart tissue also revealed significantly 
higher levels of HO-1 in the SCSE-treated group versus that of the control group. 
Confirmation of the expression of rat HO-1 in transgenic mice 
For the confirmation of rat HO-1 expression at mRNA level, RT-PCR was used and 
total RNA was isolated from the non-ischemic LVs and RVs, and S of Tg and NTg 
littermates. The PCR product was rat HO-1 specific and was detected selectively in Tg mouse 
samples by RT-PCR and Western blot. The specific band was amplified in tissues obtained 
from LV, RV and S, respectively by PCR from RNA samples of Tg mouse from different 
lines, but was absent in RNA samples of. Tg1 and Tg2 proteins were also detected by 
Western blots in the LV, RV and S of mouse hearts, but the expression of rat HO-1 proteins 
were absent in the NTg mouse myocardium. HO enzyme activities were also measured in the 
LV, RV and S obtained from NTg and Tg mice. The results show that HO activities were 
significantly increased in samples obtained from the LV, RV and S of Tg mouse hearts in 
comparison with NTg values indicating the function of Tg1 and Tg2 genes in the mouse 
myocardium. It is important to note that HO-1 mRNA and protein were not detected in NTg 
mouse myocardium either by PCR or Western blot, but HO enzyme activities were present in 
the samples of NTg mouse myocardium including LV, RV and S, respectively, indicating that 
measured HO enzyme activity involves all isoforms such as HO-1, HO-2 and HO-3. Thus, the 
differences in HO enzyme activities between NTg and Tg in the LV, RV and S were clearly 




The effect of HO-1 expression on the functions of left ventricles 
Before the induction of ischemia significant changes were not detected between NTg 
and HO-1 Tg groups in HR, CF, AF, AOP and AOPdp/dt. Upon reperfusion, the post-
ischemic recovery of CF, AF, AOP and AOPdp/dt were observed in the HO-1 Tg group in 
comparison with the NTg values without any significant differences in HR. Thus, for 
instance, after 30 and 120 min. of reperfusion, AF was significantly increased from its NTg 
control values of 0.9 ± 0.1 ml/min. and 0.8 ± 0.1 ml/min. to 2.3 ± 0.2 ml/min. (p <0.05) and 
2.2 ± 0.2 ml/min. (p <0.05) in the Tg group, respectively. The same pattern was observed in 
the post-ischemic recovery in CF, AOP and AOPdp/dt. The results also show that 50 µmol/kg 
of SnPPIX, an HO enzyme inhibitor, abolished the post-ischemic recovery of cardiac function 
in comparison with the observed protection in the HO-1 Tg group. Thus, the values obtained 
in the HO-1 Tg + SnPPIX group were not statistically significant in comparison with the NTg 
values. 
 
Evaluation of changes in tissue carbon monoxide level 
It is shown that in HO-1 Tg hearts subjected to 20 min. of ischemia followed by 120 
min. of reperfusion, a substantial increase in CO production was observed in comparison with 
the NTg myocardium. However, the endogenous production of CO in the HO-1 Tg 
myocardium treated with SnPPIX was detected at relatively low level. 
 
Evaluation of changes in the intracellular ion contents affected by different 
HO-1 expression levels 






 contents were not significantly varied between 
NTg, HO-1 Tg and HO-1 Tg + SnPPIX groups before the induction of ischemia. However, 




 contents were significantly 
reduced after 20 min. of ischemia followed by 120 min. of reperfusion in the HO-1 Tg group 
in comparison with the NTg and HO-1 Tg + SnPPIX values. In addition, the left ventricular 
tissue K
+
 content was significantly elevated (261 ± 8 _mol/g dry weight, p <0.05) in the HO-1 
Tg group compared to the K
+
 loss measured in the NTg group (229 ± 5 µmol/g dry weight). In 







 contents to those of the NTg group. In other words, SnPPIX 
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 loss in the HO-1 Tg group in the ischemic/reperfused myocardium. The values 
measured in the SnPPIX group were the same to the NTg mouse hearts after 20 min. of 
ischemia followed by 120 min. of reperfusion. 
 
Differencies in infarct size and incidence of ventricular fibrillation 
depending on HO-1 expression 
The infarct size was markedly reduced from its NTg control value of 37 ± 4% to 20 ± 
6% (*p <0.05) in the HO-1 Tg group. However, in the HO-1 KO hearts, the infarct size was 
significantly increased to 47 ± 5% (*p <0.05) in comparison with NTg group. We had 
measured the incidence (%) of reperfusion-induced VF as total (sustained and non-sustained) 
and sustained VF in NTg, Tg and KO mouse groups. The incidence of reperfusion- induced 
total and sustained VF was significantly reduced from their NTg control values of 92% and 
83% to 25% (*p <0.05) and 8% (*p <0.05), respectively, in the HO-1 Tg group. In the KO 
group, the incidence of reperfusion induced total and sustained VF were 100% and 100%, 




Cardiovascular disorders affect millions of people all over the world. Despite the 
improvement of our knowledge of clinical sciences especially on the pathogenesis of different 
diseases and possible risk factors, mortality statistical data show only a very slight 
improvement in the past decades. Recently, an unspoken but considerable call has appeared 
for treating diseases not only with synthetic, but natural compounds and also to prevent 
disorders by functional foods and dietary supplements, especially in cardiovascular cases. 
Previous results of investigation of our research team show that SCSE protects the retina 
against I/R at least by part via the induction of hemeoxygenase-1 (HO-1). This protein, which 
is also known as heat shock protein-32 plays a crucial role in stress response of the cells and 
helps to the cell survival mechanisms upon oxidative stress acting against reactive oxidative 
species (ROS). This oxidative biochemical process result in an inbalance between oxidative 
species and antioxidants. It is connected to almost uncountable pathophysiological processes, 
mainly cardiovascular diseases. ROS plays role in signaling under physiological conditions, 
but if the generation of these species is greater than the antioxidant capacity, then cellular 
injury or even cellular death may happen. Beside endogen antioxidants, applying outsource 
antioxidants under such conditions could be critical in order to protect the tissue. These 
substances are able to reduce I/R caused cardiovascular injury through several biochemical 
pathways. 
During the analysis of the sour cherry seed extract (SCSE) many different biologically active 
components were identified such as cyanides, polyphenols,
 
flavonoids, vegetable acids, pro- 
and anthocyanidines, trans-resveratrol, stilbenes and catechins. Many of these are powerful 
natural antioxidants. In our present investigations we have tested rat hearts after 8 weeks of 
SCSE treatment. This study demonstrates that administration of SCSE to animals at a dose 
shown in previous work to mediate cardioprotection, for a time period double that previously 
used, resulted in superior postischemic cardiac function versus drug-free control animals. The 
significant improvement in multiple cardiac functions, may have particularly strong relevance 
to the development of post-I/R clinical interventions to reduce severity of cardiovascular 
endothelial function. In these experiments, no sign of any adverse effect of SCSE treatment 
was observed. It is acknowledged that animals in this study were not specifically monitored 
for toxic effects. However, none was expected based on outcomes of toxic studies 
demonstrating negligible liver and kidney toxicity of the material in animals, even at dosages 
in excess of therapeutic value. Reduction in postischemic infarct size was also observed in 
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SCSE-treated animals. Moreover, consistent with our previous work, Western blot data show 
the enhanced level of Bcl-2, supporting the antiapoptotic and cytoprotective effect of SCSE. 
Adaptive/protective responses mediated by SCSE have previously been demonstrated to 
correlate with HO-1 induction as described in studies by the authors showing the capacity of 
SCSE to protect against ischemic damage to both retinal and cardiac tissue. The protective 
effects of the extract on tissue correlated significantly with elevated HO-1 protein detected by 
Western blotting and immunohistochemistry. Experiments to determine the effect of SCSE 
treatment on antiapoptotic signaling were conducted with the objective of providing insight 
into how the product might be used to modulate rates of cell death in cardiac tissue so as to 
optimize stable tissue homeostasis. Of particular importance to the accomplishment of these 
research goals is identification of how redox balance and metabolic energy utilization by 
cardiomyocytes is altered by I/R injury in ways that promote inflammatory tissue damage and 
remodeling of heart tissue. Examples of such strategies are provided by demonstrations that 
pharmacological interventions that negatively regulate apoptosis, particularly through effect 
on mitochondrial function are cardioprotective after I/R injury. An antiapoptotic property of 
SCSE was suggested by an earlier study by the authors. This study reveals increased Bcl-2 
levels as a result of SCSE treatment, which support the author’s previous findings. Some 
particularly interesting results have been obtained by examination of the effect of resveratrol, 
a cytoprotective polyphenol on cardiac tissue. This compound was shown to inhibit 
cardiomyocyte apoptosis induced by doxorubicin treatment in lymphoma nude mice. The 
aforementioned study revealed enhanced Bcl-2 and reduced Bax expression levels in hearts of 
mice treated with resveratrol before and during doxorubicin treatment in comparison with 
animals treated with doxorubicin alone. The protective effect and the modified ratio of Bcl-
2/Bax of resveratrol were reversed by zinc protoporphyrin IX (HO-1 inhibitor) indicated a 
correlation of HO-1 and Bcl-2. Our study also indicates a HO-1/Bcl-2 axis in the protective 
effect of SCSE. Additional demonstration of the protective effect of HO-1 increased by plant 
extract induction was observed by the anti-inflammatory action of genipin, an aglicon of 
geniposide. In this (aforementioned) study, the authors demonstrated a PI3-kinase-JNK1/2-
Nrf2 cascade as a possible underlying mechanism in genipin-induced HO-1 expression. The 
role of PI3K was also suggested in the oleanolic acid–induced HO-1 expression, which 
contributes to the possible protective effect of oleanolic acid in vascular smooth muscle cells 
against oxidative stress induced cellular damage. The study revealed the contribution of the 
activation of Akt and Erk to the Nrf2 nuclear localization and the subsequent HO-1 induction. 
The role of Nrf2 in the HO-1 induction by Ginkgo biloba whole-leaf extract was also reported 
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in vascular smooth muscle cells, and this pathway is suggested to play an important role of the 
antiatherogenic effect of this plant material. Based on our results, we cannot rule out the 
additional role of Akt to the protective effect of SCSE, but this study did not confirm an 
existence of a potential HO-1/Akt axis. There were no significant increases in the p-Akt/Akt 
ratio in hearts from SCSE-treated animals. It is nevertheless acknowledged that this study 
would have benefitted by a more comprehensive evaluation of signaling mechanisms by 
which SCSE-mediated increases in HO-1 expression occurred. 
Furthermore, transgenic mice expressing high levels of HO-1 exhibit reduced 
susceptibility to I/R-induced damage. In recent years, the concept of the modification in 
various gene expressions or repressions has emerged as new mechanisms and therapeutic 
tools for the induction of protection in ischemic/reperfused tissues. It is now also relatively 
well accepted that many human vascular diseases such as hypertension, heart failure, organ 
transplantation and arrhythmias can be treated with various interventions at a level of 
underlying genetic mechanisms. Certain studies show a substantial reduction in the expression 
of HO-1 mRNA and its protein with a causative reduction in the HO-1 enzyme activity in 
fibrillated ischemic/reperfused rat myocardium. Furthermore, HO-1 KO mouse hearts 
displayed a reduced left ventricular function after ischemia/reperfusion. If HO-1 system has a 
crucial role in the protection against ischemic/reperfusion-induced injury in the myocardium, 
with the enhanced expression of the HO-1, more ischemic tissue can be salvaged. Therefore, 
in the present study, because the HO-1 system can play a crucial role in the pathology of the 
ischemic/reperfused myocardium, we decided to approach the question from a different angle 
using HO-1 Tg mouse hearts. We generated HO-1 overexpressing Tg mice with an elevation 
in baseline HO enzyme activity by about 50% in the LV, RV and S, respectively. Thus, the 
application of a genome-based transgene resulted in expression levels in relation with 
increased HO enzyme activities in comparison with those of HO activities levels detected in 
the LV, RV and S obtained from NTg mice. Although, in our studies, the very similar 
homology between the mouse and rat HO-1 made it impossible to differentiate the HO-1 and 
Tg-induced enzyme activities, but we were able to distinguish them at mRNA level. In 
addition, our results obtained in NTg, HO-1 Tg and Tg-SnPPIX treated mouse hearts, we 
favour the idea that increased endogenous CO production levels in the myocardium represents 
the major signal transduction responsible for HO-1 related protection reflected in the 
improvement of the recovery in post-ischemic cardiac function, reduction of the incidence of 
reperfusion induced VF and infarct size connected to the recovery of cellular ion contents. 
Our results further supported by the complete loss of cardiac protection in the Tg 
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ischemic/reperfused mice treated with SnPPIX, the inhibitor of HO enzyme. The exact 
mechanism by which HO-1 induces cardiac protection remains to be elucidated; however, one 
of the most significant protective mechanisms of the HO system can be explained by the 
generation of endogenous CO and its signalling mechanism. CO could suppress cell apoptosis 
suggesting that the anti-apoptotic effect of HO-1 is mediated via the generation of CO. 
Another possible cellular signalling mechanism of CO is associated with the guanylyl cyclase 
activation and tissue levels of guanosine monophosphate (cGMP) and adenosine 
monophosphate (cAMP) in isolated ischemic/reperfused myocardium. Very low 
concentrations of CO, in the perfusion buffer, afford a significant protection against the 
ischemia/reperfusion-induced damage in isolated buffer perfused hearts. The isolated buffer 
perfused heart could be an ideal model to study the direct effect of exogenous CO on cardiac 
function and molecular signalling because the blood and its elements are excluded from the 
model, thus the oxygen transport to cells and tissues is not directly damaged via the 
CO/blood/haemoglobin system. Previous results have shown that low concentrations of 
exogenous CO protect the isolated ischemic/reperfused myocardium and act by increasing 
tissue cAMP and cGMP levels. Indeed, a moderate increase in cAMP content could lead to 
arrhythmogenesis and development of various arrhythmias by elevating cytosolic calcium 
levels in the ischemic and post-ischemic myocardium. It is of interest tonote that multiple 
increases in cGMP levels could mask and interfere with the arrhythmogenic effects of cAMP 
leading to the suppression of reperfusion-induced VF in the myocardium. The significant 
increase in cGMP levels can be related to guanylate cyclase activities in CO-treated 
myocardium, and suggests that induction of guanylate cyclase-cGMP system via CO 
signalling is essential for cardioprotection in ischemic/reperfused hearts. However, not only 
the absolute levels of cGMP and cAMP but also the ratio of these two nucleotides are critical 
factors that determine the recovery of post-ischemic cardiac function after ischemia and 
reperfusion. Thus, the lower the cAMP/cGMP ratio is during ischemia, the better is the post-
ischemic cardiac recovery achieved in isolated ischemic/reperfused hearts. Although not 
specifically studied in the present investigation at molecular level, it is of interest to note the 
findings of Piantadosi et al. with myocardial cells. In their studies, Piantadosi et al. implicated 
the role of HO-1/CO pathway in mitochondrial biogenesis through Akt1 activation involving 
nuclear factor erythroid 2-related factor (Nrf-2) expression, downstream GSK-3β blockade 
and Nrf2 nuclear translocation leading to Nrf2-dependent activation of nuclear respiratory 
factor (NRF)-1 transcription. Their finding suggest HO-1/CO, by sequentially activating the 
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aforementioned two transcription factors, as a remarkable component of a prosurvival 
program of mitochondrial biogenesis connected to cellular antioxidant defence mechanisms. 
Today, when so many advances and efforts are being made in molecular biology and genetics, 






 in both clinical 
and experimental studies. As a gap, in changes between various gene expression and/or 
repression and the function of myocardial tissue, could closely be connected with changes in 
myocardial tissue ion contents. An important finding such a final endpoint of our present 
study was the myocardial K
+
 – conserving effect related to the prevention of cellular Na+ and 
Ca
2+
 gains in Tg myocardium, and this cardiac protection can be reversed by SnPPIX, an HO-
1 inhibitor. HO-1–bilirubin system and one of its by-products, CO, are essential for regulation 
of cardiac function and ion transport across cell membranes via the stabilization of various 
Na, K and Ca ion channels possibly by an effect exerted on Na-K-ATPase, and these transient 
outward and inward currents are thought to underline the delayed after depolarization that can 
be observed after the action potential in Ca-loaded cardiac tissue propagating rhythm 
disturbances. There are significant differences in the cellular signalling mechanisms induced 
by CO when they are compared with the actions of other interventions that elevate cyclic 
nucleotides in tissues. In our study we have shown that CO level was significantly increased 
in the HO-1 Tg mouse myocardium. However, we did not measure CO levels during 
reperfusion; therefore, we believe that the elevated CO production can be responsible for the 
protection during reperfusion in Tg myocardium. Besides this, we cannot rule out the 
contribution of other HO-1 related molecules such as biliverdin and bilirubin in the observed 
cardiac protection. 
In conclusion, using HO-1 Tg, we have demonstrated the direct causative role of HO-1 in 
protection against ischemia/reperfusion induced injury. Specifically, our results show a 
significant recovery of post-ischemic cardiac function, prevention of the development of 
reperfusion-induced VF and reduction in infarct size. In addition, we have provided new 
insights into the ionic mechanisms by which HO-1 may contribute to the attenuation of 
reperfusioninduced arrhythmias in HO-1 Tg. We believe that these studies would help in 
developing novel therapies based on targeting HO-1 for the treatment of ischemia/reperfusion 





Despite a slight improvement on statistical data, cardiovascular diseases are still 
among the highest risk factors of mortality rates all over the world. Hungarian mortality 
indexes are far above than in the EU, therefore our resources should be focused on the 
prevention and diagnosis at the exact time. 
HO-1, a cytoprotective, antioxidant heat shock protein plays a crucial role in the 
pathogenesis of several human disorders, especially cardiovascular diseases. Based on our 
experiments carried out on HO-1 transgenic mice model HO-1 overexpression leads the 
restoration of functioning state of left ventricles after I/R injury. An unspoken but 
considerable call has appeared recently for treating diseases not only with synthetic, but 
natural compounds and to prevent disorders by functional foods and dietary supplements, 
especially in cardiovascular cases. Sour cherry seed extract experimented by our team induced 
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